Ensysce Biosciences Inc. (ENSC) is a publicly traded, clinical-stage drug company committed to delivering unique approaches to address the rampant misuse, abuse, and overdose of prescription drugs. The company's headquarters are located in San Diego, California, where a dedicated team of scientists and researchers work tirelessly to pioneer solutions in the areas of substance use disorders, pain, and overdose.
Ensysce Biosciences specializes in developing a portfolio of powerful yet safe and non-addictive pain treatments using its signature MPAR (Multi Pill Abuse Resistance) and TAAP (Trypsin Activated Abuse Protected) technologies. These novel technologies aim to provide solutions to the opioid crisis, which has resulted in nearly 50,000 overdose deaths per year in the United States alone.
The company's MPAR technology is incorporated into its lead product: PF614, an opioid prodrug created to provide sustained relief from chronic pain without the risk of addiction or overdose. PF614 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and is currently in Phase I and II clinical trials.
The TAAP technology, on the other hand, is incorporated into its second lead product: BIO-MD, a superior delivery vehicle for addicting drugs such as methylphenidate (Ritalin), amphetamine salts (Adderall), and buprenorphine (Buprenex). BIO-MD is also in the clinical stage and has shown promise in preventing substance misuse and enabling proper medication compliance.
Besides, the company is developing an innovative Immuno-Oncology product platform, which includes carbon nanotubes for the potential treatment of cancers. This research is still in its preclinical stage.
On a broader scale, Ensysce Biosciences aims to transform the prescription drug market with its technology, focusing primarily on the safety and efficacy of therapeutics. They are driven by the mission of helping patients suffering from chronic pain and other ailments get the treatment they need without the risk of addiction or harm frequently associated with such medications.
Reaching towards this goal, Ensysce Biosciences Inc. (ENSC) continues to catalyze innovations, collaborations, and scientific investigations. By leveraging its patented technology and pushing the boundaries of traditional pain management strategies, the company is steadfast in its commitment to make a meaningful difference in patients' lives and the overall healthcare landscape.